心房顫動 Atrial Fibrillation

大腦的血液一但中斷，就會發生中風。心房顫動患者的中風猝發機率較高。中風預防是我們心血管團隊的關注重點，百靈佳殷格翰開發出第一種NOAC抗凝血劑，用以保護與預防非瓣膜性心房顫動（non-valvular atrial fibrillation）患者免於中風。

A stroke occurs when the blood supply to part of the brain is interrupted. Patients with an irregular heart beat (known as atrial fibrillation) are at increased risk of stroke. Preventing stroke in these patients is a key focus of our cardiovascular team. Boehringer Ingelheim developed the first non-vitamin K antagonist oral anticoagulant (NOAC) to protect patients with non-valvular atrial fibrillation against stroke, advancing anticoagulation care.